Eva Zusinaite1, Kaja Metskula, Riina Salupere. 1. Department of Internal Medicine, University of Tartu, Puusepa 6, Tartu 51014, Estonia. evazusinaite@hotmail.com
Abstract
AIM: To determine the prevalence of several autoantibodies in chronic hepatitis C patients, and to find out whether the pattern of autoantibodies was associated with hepatitis C virus (HCV) genotypes. METHODS: Sera from 90 consecutive patients with chronic hepatitis C were investigated on the presence of anti-nuclear (ANA), anti-mitochondrial (AMA), anti-smooth muscle (SMA), anti-liver-kidney microsomal type 1 (LKMA1), anti-parietal cell (PCA), anti-thyroid microsomal (TMA), and anti-reticulin (ARA) autoantibodies. The autoantibodies were identified by indirect immunofluorescence. HCV genotypes were determined by a restriction fragment length polymorphism analysis of the amplified 5' noncoding genome region. RESULTS: Forty-six (51.1%) patients were positive for at least one autoantibody. Various antibodies were presented as follows: ANA in 13 (14.4%) patients, SMA in 39 (43.3%), TMA in 2 (2.2%), and ARA in 1 (1.1%) patients. In 9 cases, sera were positive for two autoantibodies (ANA and SMA). AMA, PCA and LKMA1 were not detected in the observed sera. HCV genotypes were distributed as follows: 1b in 66 (73.3%) patients, 3a in 18 (20.0%), and 2a in 6 (6.7%) patients. CONCLUSION: A high prevalence of ANA and SMA can be found in chronic hepatitis C patients. Autoantibodies are present at low titre (1:10) in most of the cases. Distribution of the autoantibodies show no differences in the sex groups and between patients infected with different HCV genotypes.
AIM: To determine the prevalence of several autoantibodies in chronic hepatitis Cpatients, and to find out whether the pattern of autoantibodies was associated with hepatitis C virus (HCV) genotypes. METHODS: Sera from 90 consecutive patients with chronic hepatitis C were investigated on the presence of anti-nuclear (ANA), anti-mitochondrial (AMA), anti-smooth muscle (SMA), anti-liver-kidney microsomal type 1 (LKMA1), anti-parietal cell (PCA), anti-thyroid microsomal (TMA), and anti-reticulin (ARA) autoantibodies. The autoantibodies were identified by indirect immunofluorescence. HCV genotypes were determined by a restriction fragment length polymorphism analysis of the amplified 5' noncoding genome region. RESULTS: Forty-six (51.1%) patients were positive for at least one autoantibody. Various antibodies were presented as follows: ANA in 13 (14.4%) patients, SMA in 39 (43.3%), TMA in 2 (2.2%), and ARA in 1 (1.1%) patients. In 9 cases, sera were positive for two autoantibodies (ANA and SMA). AMA, PCA and LKMA1 were not detected in the observed sera. HCV genotypes were distributed as follows: 1b in 66 (73.3%) patients, 3a in 18 (20.0%), and 2a in 6 (6.7%) patients. CONCLUSION: A high prevalence of ANA and SMA can be found in chronic hepatitis Cpatients. Autoantibodies are present at low titre (1:10) in most of the cases. Distribution of the autoantibodies show no differences in the sex groups and between patients infected with different HCV genotypes.
Authors: R Uibo; I Talja; R Jôgi; C Janson; E Björnsson; G Boman; M Mandel; B Björkstén Journal: Int Arch Allergy Immunol Date: 1998-10 Impact factor: 2.749
Authors: P Cresta; L Musset; P Cacoub; L Frangeul; D Vitour; T Poynard; P Opolon; D T Nguyen; F Golliot; J C Piette; J M Huraux; F Lunel Journal: Gut Date: 1999-07 Impact factor: 23.059
Authors: J M Turchany; R Uibo; T Kivik; J Van de Water; T Prindiville; R L Coppel; M E Gershwin Journal: Am J Gastroenterol Date: 1997-01 Impact factor: 10.864
Authors: P Muratori; L Muratori; T Stroffolini; G Pappas; P Terlizzi; R Ferrari; S Loffreda; F Cassani; M Rapicetta; V Guadagnino; F B Bianchi; M Lenzi Journal: Clin Exp Immunol Date: 2003-01 Impact factor: 4.330
Authors: M Lenzi; S Bellentani; G Saccoccio; P Muratori; F Masutti; L Muratori; F Cassani; F B Bianchi; C Tiribelli Journal: Gut Date: 1999-09 Impact factor: 23.059